BackCERo Therapeutics Holdings - Warrants (13/02/2029) Overview

CERo Therapeutics Holdings - Warrants (13/02/2029) Receivables

Track CERo Therapeutics Holdings - Warrants (13/02/2029)'s receivables ($0) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Receivables
$0.00

Peer average

Loading

CERo Therapeutics Holdings - Warrants (13/02/2029) Receivables History

Loading

CERo Therapeutics Holdings - Warrants (13/02/2029) vs. peers: Receivables Comparison

Loading

CERo Therapeutics Holdings - Warrants (13/02/2029) Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

CERo Therapeutics Holdings - Warrants (13/02/2029) (CEROW) FAQ

CERo Therapeutics Holdings - Warrants (13/02/2029) posts a receivables of $0 as of March 2026. In the prior-year period, the figure was $0. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, CERo Therapeutics Holdings - Warrants (13/02/2029)'s receivables was $0. The latest reading is $0 (period ending March 2026). Use the history and growth charts on this page for a longer lookback.

Receivables is one piece of CERo Therapeutics Holdings - Warrants (13/02/2029)'s financial statement story. At $0, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for CEROW's receivables usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; CERo Therapeutics Holdings - Warrants (13/02/2029)'s other metric pages and overview cover the third.